The development of resistance remains a major obstacle to long-term disease control in cancer patients treated with targeted therapies. In BRAF-mutant mouse models, we demonstrate that although targeted inhibition of either BRAF or VEGF initially suppresses the growth of BRAF-mutant tumors, combined inhibition of both pathways results in apoptosis, long-lasting tumor responses, reduction in lung colonization, and delayed onset of acquired resistance to the BRAF inhibitor PLX4720. As well as inducing tumor vascular normalization and ameliorating hypoxia, this approach induces remodeling of the extracellular matrix, infiltration of macrophages with an M1-like phenotype, and reduction in cancer-associated fibroblasts. At the molecular level, this therapeutic regimen results in a de novo transcriptional signature, which sustains and explains the observed efficacy with regard to cancer progression. Collectively, our findings offer new biological rationales for the management of clinical resistance to BRAF inhibitors based on the combination between BRAFV600E inhibitors with anti-angiogenic regimens.

VEGF blockade enhances the antitumor effect of BRAFV600E inhibition

COMUNANZA, Valentina;CORA', DAVIDE;ORSO, FRANCESCA;MIDDONTI, EMANUELE;DI NICOLANTONIO, Federica;MEDICO, Enzo;SANGIOLO, Dario;TAVERNA, Daniela;BUSSOLINO, Federico
Last
2017-01-01

Abstract

The development of resistance remains a major obstacle to long-term disease control in cancer patients treated with targeted therapies. In BRAF-mutant mouse models, we demonstrate that although targeted inhibition of either BRAF or VEGF initially suppresses the growth of BRAF-mutant tumors, combined inhibition of both pathways results in apoptosis, long-lasting tumor responses, reduction in lung colonization, and delayed onset of acquired resistance to the BRAF inhibitor PLX4720. As well as inducing tumor vascular normalization and ameliorating hypoxia, this approach induces remodeling of the extracellular matrix, infiltration of macrophages with an M1-like phenotype, and reduction in cancer-associated fibroblasts. At the molecular level, this therapeutic regimen results in a de novo transcriptional signature, which sustains and explains the observed efficacy with regard to cancer progression. Collectively, our findings offer new biological rationales for the management of clinical resistance to BRAF inhibitors based on the combination between BRAFV600E inhibitors with anti-angiogenic regimens.
2017
9
2
219
237
http://embomolmed.embopress.org/content/9/2/219.long
http://embomolmed.embopress.org/content/early/2016/12/14/emmm.201505774
Angiogenesis; Drug resistance; Extracellular matrix; Myeloid infiltration; Vascular normalization; Molecular Medicine
Comunanza, Valentina; Cora', Davide; Orso, Francesca; Consonni, Francesca Maria; Middonti, Emanuele; DI NICOLANTONIO, Federica; Buzdin, Anton; Sica, Antonio; Medico, Enzo; Sangiolo, Dario; Taverna, Daniela; Bussolino, Federico
File in questo prodotto:
File Dimensione Formato  
2016_Comunanza_EMBOMolMed_Article_IRIS.pdf

Accesso aperto

Descrizione: Articolo principale
Tipo di file: PDF EDITORIALE
Dimensione 6.69 MB
Formato Adobe PDF
6.69 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1623496
Citazioni
  • ???jsp.display-item.citation.pmc??? 17
  • Scopus 31
  • ???jsp.display-item.citation.isi??? 32
social impact